Atherothrombotic disease, including coronary artery disease (CAD), can lead to cardiovascular events (CV) events, ultimately creating substantial levels of patient morbidity and a shortened life expectancy. Treatment of CAD is always based in medication but may also be supplemented by lifestyle modification and invasive procedures [Doenst, 2022; Reed, 2022]. New targets to combat CAD may be on the horizon, such as the upregulation of the purine synthesis gene, ATIC, which is reported in injured vessels and atherosclerotic lesions [Ma, 2022]. There is an established medical management of CAD [Knuuti, 2020; Malakar, 2019; Reed, 2022; Smith, 2011] which includes beta-blockers [Knuuti, 2020]. Guidelines on optimal CV medical therapy (American Heart Association/American College of Cardiology, European Society of Cardiology [Smith, 2011; Knuuti, 2020; Reed, 2022]) recommend beta-blockers for ≥3 years for patients with prior MI and indefinitely in those patients with left ventricular dysfunction and the European guidelines recommend beta-blockers as first-line treatment to control heart rate and relieve CAD symptoms [Knuuti, 2020]. Beta-blockers can also be considered for secondary prevention in patients with CAD or compensated heart failure with reduced ejection fraction and there is evidence for the use of long-acting beta-blockers in patients with tachycardia-related hypertension [Cierpka-Kmieć, 2020]. Managing CAD risk factors, lifestyle modification, polypharmacy, awareness and treatment of co-morbidities and factors indicating coronary revascularisation should all be considered in the CAD treatment regimen [Braun, 2018].